Effect of pump flow mode of novel left ventricular assist device upon end organ perfusion in dogs with doxorubicin induced heart failure.
End organ effects of nonpulsatile (NP) and pulsatile (P) left ventricular assist device (LVAD) flow were compared in a canine model of doxorubicin-induced heart failure. After heart failure induction, a prototype bimodal LVAD was implanted. Hemodynamics, cardiac dimensions, and myocardial metabolism were monitored with the LVAD off (baseline) and on (in NP and P modes at 70% or 100% power). End organ perfusion was assessed by colored microsphere analysis. Seven dogs were used: two died before pump implantation and were excluded from analysis, and the remaining five survived to study termination. At 70% NP, ascending aortic flow and myocardial oxygen consumption (MVO2) decreased significantly. At 100% NP, LV dimensions decreased, aortic systolic, pulse, and LV pressures decreased but not significantly, and ascending aorta flow reversed. At 100% NP, coronary blood flow, MVO2, and LV free wall subepicardial and subendocardial blood flows decreased significantly. However, as NP support increased, the subepicardial/subendocardial blood flow ratio remained near baseline. At 100% NP, right ventricular perfusion decreased but not significantly, cerebral perfusion decreased significantly, and renal perfusion stayed constant. P mode results were similar, except that ascending aorta flow decreased significantly at 100% P instead of reversing as at 100% NP. These results suggest that end organ perfusion is not differentially affected by LVAD flow mode during chronic heart failure.
Eya
Kazuhiro
K
Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77225-0345, USA.
Tuzun
Egemen
E
Conger
Jeff
J
Chee
Hyun K
HK
Byler
Denise
D
Nojiri
Chisato
C
Frazier
O H
OH
Kadipasaoglu
Kamuran
K
D000818:Animals; D001011:Aorta / Q000502:physiology; D001013:Aorta, Thoracic / Q000502:physiology; D001794:Blood Pressure / Q000502:physiology; D015908:Counterpulsation; D004285:Dogs; D004317:Doxorubicin; D006333:Heart Failure / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D006353:Heart-Assist Devices; D006439:Hemodynamics; D009206:Myocardium / Q000648:ultrastructure; D010477:Perfusion; D011673:Pulsatile Flow; D014463:Ultrasonography; D016277:Ventricular Function, Left / Q000502:physiology*
D004317:Doxorubicin